No difference in death rates among patients exposed to common rheumatoid arthritis drugs, study suggests
Wednesday, August 8, 2012 - 08:30
in Health & Medicine
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade).